🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Jefferies starts 'Buy' on BioLife Solutions stock, eyes set on cell therapy market

EditorEmilio Ghigini
Published 04/04/2024, 04:59 AM
BLFS
-

On Thursday, BioLife Solutions (NASDAQ:BLFS) stock, received a positive outlook from Jefferies, initiating coverage with a Buy rating and setting a price target of $22.00. The endorsement comes as the company prepares to divest its freezer business, a move expected to streamline its operations.

Jefferies highlighted that the divestiture of the freezer segment will allow BioLife Solutions to present a "cleaner story" as a pure-play entity in the cell and gene therapy space. This strategic shift is anticipated to lead to a more focused business model revolving around its cell processing tools and storage platform. With over 95% recurring revenue, the firm is poised for structurally higher double-digit growth, significant margin expansion opportunities, and improved cash flow.

The financial institution drew parallels between BioLife Solutions and other pure-play bioproduction companies, noting its specialized offerings to a diversified client base in both clinical and commercial biotech sectors. These factors contribute to a solid competitive moat due to sticky revenue streams.

The price target of $22.00 set by Jefferies is based on approximately 8.5 times the company's estimated 2025 enterprise value to revenue, a premium compared to peers but aligned with industry standards. This valuation reflects a roughly 35% discount to Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), yet remains consistent with the market positioning of other high-growth companies in the sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.